| title | layout |
|---|---|
IDAMAC |
page |
- All samples, generated data and materials will be governed by the IDAMAC.
- The IDAMAC will authorise use of samples and dissemination of results.
- Disputes will be resolved by majority vote of the IDAMAC.
The IDAMAC will comprise eight senior, independent people with broad representation including research funders, academia, medicine, industry and public health. These individuals will not be involved in the acquisition or analysis of samples or data.
The committee will meet virtually on an ad hoc basis as needed. New appointments to the IDAMAC to replace retiring members will be proposed by the chair and approved by majority vote of the committee.
Members:
- Jeremy Farrar (IDAMAC Chair)(Wellcome Trust; research funder)
- Jonathan Van Tam (DCMO)
- Katherine Maitland (Oxford University; academia)
- Nahoko Shindo (WHO; public health)
- John Marshall (Chair, WHO coronavirus research prioritisation panel; clinical medicine)
- Danny McAuley (NIHR EME Chair; research funder)
- Matthew Downham (Associate Director, BioPharmaceuticals Development (Influenza Vaccines)
- Stephen Lockhart (Vice President, Vaccine Clinical R&D. Europe and Asia-Pacific Head at Pfizer)
Administrator: - Wilna Oosthuyzen
The IDAMAC will operate according to the following principles:
- materials and data must be used urgently in the national interest
- studies will be prioritised where there is a high probability of:
- research or development activity aligned to the key research priorities set by UKRI and WHO;
- delivery of results within the timeframe of the outbreak;
- for commercial product development, rapid upscaling and deployment of usable products to market (e.g. CE marking, regulatory approvals in place)
All custodians of research samples will sign an MOU stating they will abide by the decisions of the committee.